Effect of Postural Change on Hemoglobin Level in Patients on the Intensive Care Unit

NCT ID: NCT06438458

Last Updated: 2024-06-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-17

Study Completion Date

2024-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Monitoring hemoglobin levels (Hb) is important to identify anemia in hospitalized patients. Changes in posture and mobilization efforts, as demonstrated by previous research, can lead to significant shifts in Hb concentrations. This phenomenon has not been studied in ICU patients.

This study aims to investigate whether postural changes and mobilisation affect Hb in ICU patients. We hypothesize that significant Hb shifts may occur, potentially leading to misinterpretations of anemia and unnecessary diagnostic and therapeutic workup. Understanding this impact can guide clinical practice and prevent unwarranted interventions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale:

Monitoring hemoglobin levels (Hb) is important to identify anemia in hospitalized patients. Changes in posture and mobilization efforts, as demonstrated by previous research, can lead to significant shifts in Hb concentrations. Low Hb levels due to these shifts are termed 'postural pseudoanemia'.

This phenomenon has not been studied in ICU patients. Many factors may affect Hb concentrations in ICU patients, including plasma volume shifts, bleeding, repeated phlebotomies, hemolysis, bone marrow suppression and functional iron deficiency. When this leads to significant anemia, patients may be treated with red blood cell transfusions. However, blood transfusions have been associated with adverse reactions and should only be performed for appropriate indications. If postural pseudoanemia occurs in ICU patients this could lead to patient harm through inadvertent investigations and red blood cell transfusions. The occurrence of postural pseudoanemia in ICU patients may differ from previous studies because ICU patients are more frequently immobilized for more prolonged periods.

This study aims to investigate whether postural changes affect Hb in ICU patients. We hypothesize that significant Hb shifts may occur, potentially leading to misinterpretations of anemia and unnecessary diagnostic and therapeutic workup. Understanding this impact can guide clinical practice and prevent unwarranted interventions.

Objective:

Main objective: To assess Hb levels in ICU patients upon a change in posture from supine to upright and following mobilization to a chair.

Secondary objectives:

To seek correlations between hemoglobin shifts and changes in serum albumin concentrations upon a change in posture from supine to sitting and following mobilization to a chair.

To seek correlations between hemoglobin shifts and changes in serum uric acid concentrations upon a change in posture from supine to sitting and following mobilization to a chair.

To seek correlations between hemoglobin shifts and levels of CRP and ESR upon a change in posture from supine to sitting and following mobilization to a chair.

To compare hemoglobin concentrations following \> 6 hours in supine position at 24 hours with pre-intervention levels for patients remaining in the ICU.

Any other changes seen in the lab measurements or vital parameters upon a change in posture?

Study design:

Prospective uncontrolled interventional study.

Study population:

Patients \> 18 years old, admitted to the intensive care unit.

Intervention:

All patients will undergo a change in posture from supine to upright, followed by mobilization to a chair.

Main study parameters/endpoints:

Relative percentage change in Hb.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Blood samples are taken before and after the interventions
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hb in different positions

Hemoglobin concentration after sitting in bed (passively) for \>30 min, and after mobilization to a chair for \>30 min

Group Type EXPERIMENTAL

Postural change from supine to sitting

Intervention Type PROCEDURE

Patients go from supine to sitting position in bed (passive)

Mobilization to a chair

Intervention Type PROCEDURE

Patients go from the bed to sitting in a chair (active)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Postural change from supine to sitting

Patients go from supine to sitting position in bed (passive)

Intervention Type PROCEDURE

Mobilization to a chair

Patients go from the bed to sitting in a chair (active)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age over 18 years, of any gender and ethnic background
* Admitted to the intensive care unit
* Able to give informed consent
* Patients with an arterial line as part of their treatment plan.
* Patients able to remain seated in chair for at least 30 minutes
* Patients able to remain supine overnight for at least 6 hours

Exclusion Criteria

* Delirium or inability to give informed consent
* Inability to understand written information in Dutch
* Patients on artificial ventilation
* Orotracheally intubated patients (spontaneous breathing through a tracheostomy cannula is allowed)
* Patients treated with noradrenaline \> 0.05 ug/kg/min
* Patients treated with argipressin
* Patients who received a blood transfusion within 24 hours before measurements
* Patients who received \> 3 L of fluids within 24 hours before measurements
* Patients who received \> 500 ml of iv fluids within 4 hours of measurements
* Severe restlessness or inability to remain supine for 6 hours before initial blood sampling
* Patients being treated with diuretics
* Patients admitted with:
* Decompensated right heart failure
* Pulmonary hypertension
* Pulmonary embolism
* Active bleeding or risk of \>100 ml blood loss
* Hematological disorder/malignancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Deventer Ziekenhuis

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alfred L van Steveninck, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Deventer Ziekenhuis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Deventer Hospital

Deventer, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alfred L van Steveninck, M.D., Ph.D.

Role: CONTACT

+31570535346

Huub LA van den Oever, M.D.

Role: CONTACT

+31570535346

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alfred L van Steveninck, M.D., Ph.D.

Role: primary

+31570535346

Huub LA van den Oever, M.D.

Role: backup

+31570535346

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL86966

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.